Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MannKind Corporation - Common Stock
(NQ:
MNKD
)
5.540
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about MannKind Corporation - Common Stock
< Previous
1
2
3
4
5
6
Next >
What's Going On With MannKind Stock Friday?
↗
February 27, 2026
MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations.
Via
Benzinga
Why MannKind Stock Tumbled on Thursday
↗
February 26, 2026
Mr. Market was hoping for a better fourth quarter than the company delivered.
Via
The Motley Fool
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026
↗
February 26, 2026
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
February 25, 2026
Via
Chartmill
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’
↗
February 25, 2026
United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.”
Via
Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026
↗
January 08, 2026
Via
Stocktwits
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors?
↗
December 23, 2025
Via
Stocktwits
MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century
↗
November 06, 2025
Via
Stocktwits
Here are the top movers in Wednesday's session.
↗
February 25, 2026
Via
Chartmill
The market is filled with gapping stocks in Wednesday's session.
↗
February 25, 2026
Via
Chartmill
Why Did MNKD Stock Jump Over 7% In Pre-Market Today?
↗
January 26, 2026
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.
Via
Stocktwits
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
↗
December 24, 2025
This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity.
Via
The Motley Fool
Topics
Regulatory Compliance
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters
↗
November 05, 2025
Via
Stocktwits
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
↗
September 02, 2025
Via
Stocktwits
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
↗
August 27, 2025
Via
Stocktwits
Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop
↗
December 23, 2025
With shares battered and leverage rising, this quiet trim raises a sharper question about how much patience investors should have left.
Via
The Motley Fool
Topics
Regulatory Compliance
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year
↗
December 23, 2025
The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus investment case.
Via
The Motley Fool
Topics
Regulatory Compliance
Supply Chain
MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise
↗
November 05, 2025
MannKind (MNKD) Q3 2025 results beat revenue and EPS estimates. The biopharma's shares rose on strong performance and strategic updates, including the scPharmaceuticals acquisition.
Via
Chartmill
Topics
Earnings
10 Health Care Stocks Whale Activity In Today's Session
↗
September 09, 2025
Via
Benzinga
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’
↗
August 06, 2025
Via
Stocktwits
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
↗
September 02, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
September 02, 2025
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Tuesday's pre-market session: top gainers and losers
↗
September 02, 2025
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 02, 2025
Via
Benzinga
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
↗
August 25, 2025
The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.
Via
Stocktwits
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
↗
August 25, 2025
MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity.
Via
Benzinga
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
↗
August 25, 2025
The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.
Via
Stocktwits
MannKind (MNKD) Q2 Revenue Rises 6%
↗
August 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
World Trade
MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market
↗
August 06, 2025
MannKind Corp (MNKD) missed Q2 2025 revenue and EPS estimates, causing a 3.8% pre-market drop. Despite the miss, strategic moves like Blackstone's $500M financing and product pipeline progress offer...
Via
Chartmill
Topics
Earnings
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
